Aquestive Therapeutics Inc (AQST)vsZoetis Inc (ZTS)
AQST
Aquestive Therapeutics Inc
$3.88
-1.27%
HEALTHCARE · Cap: $485.74M
ZTS
Zoetis Inc
$116.71
+0.67%
HEALTHCARE · Cap: $51.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 21153% more annual revenue ($9.47B vs $44.55M). ZTS leads profitability with a 28.2% profit margin vs -1.9%. ZTS earns a higher WallStSmart Score of 64/100 (C+).
AQST
Avoid22
out of 100
Grade: F
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AQST.
Margin of Safety
-29.1%
Fair Value
$99.69
Current Price
$116.71
$17.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Trading at 14.9x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AQST
AQST has a balanced fundamental profile.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : AQST
The primary concerns for AQST are EPS Growth, Market Cap, Return on Equity.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
AQST profiles as a turnaround stock while ZTS is a value play — different risk/reward profiles.
AQST carries more volatility with a beta of 1.59 — expect wider price swings.
AQST is growing revenue faster at 9.7% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (64/100 vs 22/100), backed by strong 28.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aquestive Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?